The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) will today outline moves to deepen collaboration with the US Food and Drug Administration (FDA) on medical technology regulation, with initiatives to accelerate innovation, strengthen patient safety, and reduce transatlantic barriers to market access.
MHRA National AI Commission launched with UK and US experts to shape safe, transparent use of AI in healthcare .New international reliance routes to improve international investment and UK access to medical devices already approved by trusted regulators, including the US FDA .
The US and UK share a common goal – ensuring patients benefit quickly and safely from the latest medical innovations. With US-based thought leadership inputting to our new National AI Commission, and new reliance frameworks for FDA approvals, we are laying the foundations for a truly global, innovation-ready regulatory environment.
【MORE】